PD-1 inhibitor nivolumab monotherapy has been provento improve prognosis in HCC, and the addition of CTLA-4 inhibitor ipilimumab seemed to augment the impact, suggested by elevated ORR and OS in the combination group (Yau et al., 2022). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.